Detalles de la búsqueda
1.
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Am J Gastroenterol
; 118(2): 317-328, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191274
2.
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Dermatology
; 238(3): 438-447, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34710876
3.
Characteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database.
J Drugs Dermatol
; 20(10): 1127-1131, 2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34636519
4.
Determinants of patient and physician treatment satisfaction in moderate-to-severe psoriasis: a multinational survey of psoriasis patients.
Dermatol Online J
; 27(10)2021 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35130382
5.
Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
J Med Econ
; 26(1): 691-700, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37130075
6.
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
Curr Med Res Opin
; 39(8): 1167-1174, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37492015
7.
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Dermatol Ther (Heidelb)
; 13(2): 629-640, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36585606
8.
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
Dermatol Ther (Heidelb)
; 13(2): 487-504, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484917
9.
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Adv Ther
; 40(5): 2493-2508, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36930429
10.
Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
J Dermatolog Treat
; 33(1): 518-524, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479140
11.
Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
J Dermatolog Treat
; 33(4): 2270-2277, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264149
12.
Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
Curr Med Res Opin
; 38(7): 1093-1101, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35475385
13.
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.
Dermatol Ther (Heidelb)
; 12(3): 741-752, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35212934
14.
Predicting Poor Outcomes Among Individuals Seeking Care for Major Depressive Disorder.
Psychiatr Res Clin Pract
; 4(4): 102-112, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36545504
15.
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.
Dermatol Ther (Heidelb)
; 12(4): 971-987, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305255
16.
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
Dermatol Ther (Heidelb)
; 12(1): 97-119, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34822121
17.
Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United States.
Crohns Colitis 360
; 3(4): otab076, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36777272
18.
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
J Dermatolog Treat
; 32(6): 595-602, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31714168
19.
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
J Med Econ
; 22(12): 1268-1273, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31199173
20.
Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis.
J Med Econ
; 22(12): 1290-1297, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31262226